Truspoilt
The Comeback Creator includes GLP-1, Sermorelin, and NAD+
GLP-1 is a naturally occurring hormone that supports the body’s mechanisms for metabolic balance after meals.1
As routines get busy and stress builds, many people find it harder to stay consistent with nutrition, movement, and daily habits.2
NAD+ (Nicotinamide Adenine Dinucleotide) is a natural coenzyme found in every cell of your body.8
It plays an important role in metabolic processes, helping cells turn nutrients into usable energy while supporting many everyday cellular functions.8
As we age, NAD+ levels naturally decline. This typical biological change can influence how efficiently our cells function over time.9
Click ‘See If You Qualify’ and purchase your plan. After checkout, you’ll complete an online intake form.
A healthcare provider will review your information to determine if the plan is appropriate for you.
If approved, your kit ships in discreet packaging. Not approved? You’ll receive a full refund.
If your goal is to rebuild momentum and support long-term consistency, longevity medicine works best when treated as medical care—not experimentation.
If approved, your treatment is compounded by a USA-based 503(a) pharmacy.
Our longevity plans are designed for men who want to reset with structure, guidance, and a clear plan forward.
Your package ships within 5–7 business days. You’ll get an email with tracking information once it’s on the way.
If you wish to cancel after your provider completes your health review and writes a prescription, HelloWellness may refund your total payment minus a $50 professional services fee.
Please email info@hellowellness.health within 24 hours of your completed provider review. Requests submitted after this timeframe may not be eligible for a refund.
1Kahal H, Kilpatrick ES, Wilding JPH. Tirzepatide: a dual GIP/GLP‑1 receptor agonist for the treatment of type 2 diabetes. Diabetologia. 2023;66(1):1-14
2Schwabe L, Wolf OT. Stress prompts habit behavior in humans. J Neurosci. 2009;29(22):7191-7198
3Garvey WT, Batterham RL, Bhatta M, et al. Association between weight reduction achieved with tirzepatide and health-related quality of life in people with overweight or obesity. Obesity (Silver Spring). 2025;33(4):769-780
4Hartman ML, Sanyal AJ, Aleppo G, et al. Effects of tirzepatide on body weight and cardiometabolic risk factors in people with overweight or obesity: a post hoc analysis of the SURPASS clinical trial program. Diabetes Obes Metab. 2023;25(2):485-496
5Rubino D, Abrahamsson N, Davies M, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: a randomized clinical trial. JAMA. 2024;331(1):31-43
6Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(3):235-243
7Steiger A, Guldner J, Hemmeter U, et al. Effect of growth hormone-releasing hormone (GHRH) on sleep and sleep-related growth hormone secretion in normal young and old men. J Clin Endocrinol Metab. 1992;74(5):1109-1114
8Houtkooper RH, Cantó C, Auwerx J. NAD+ homeostasis as a hub for metabolic control in health and disease. Cell Metab. 2010;11(5):430-441. doi:10.1016/j.cmet.2010.04.001
8Verdin E, Ott M. NAD+ in aging, metabolism,and disease. Trends Cell Biol. 2015;25(9):431-441. doi:10.1016/j.tcb.2015.04.002
9Gomes AP, Price NL, Ling AZ, et al. Declining NAD+ induces a pseudohypoxic state disrupting cellular energy homeostasis and mitochondrial function in human cells. Cell Metab. 2013;17(3):392-405. doi:10.1016/j.cmet.2013.02.003
10Fang EF, Lautrup S, Ho YS, et al. NAD+ in aging: molecular mechanisms and translational implications. Trends Mol Med. 2017;23(10):899-916. doi:10.1016/j.molmed.2017.08.001
11de Picciotto NE, Gano LB, Johnson LC, et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell. 2016;15(5):973-977. doi:10.1111/acel.12488
12Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD+ in brain aging and neurodegenerative disorders. Cell Metab. 2019;30(4):630-655. doi:10.1016/j.cmet.2019.09.015